Development and evaluation of push-pull based osmotic delivery system for pramipexole

PDA Journal of Pharmaceutical Science and Technology

Volumn 62, Issue 1, 2008, Pages 22-31

  Wakode, Rajeshri ^a   Bhanushali, Roopali ^a   Bajaj, Amrita ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

Author keywords

Osmotic delivery; Osmotic pressure

Indexed keywords

ACETONE; BICARBONATE; CELLULOSE; CELLULOSE ACETATE; DICHLOROMETHANE; EXCIPIENT; LACTOSE; MACROGOL 400; MAGNESIUM STEARATE; MANNITOL; METHANOL; PHTHALIC ACID DIBUTYL ESTER; POTASSIUM CHLORIDE; POVIDONE; PRAMIPEXOLE; SODIUM CHLORIDE; WATER; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; PRAMIPEXOL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; OSMOTIC PRESSURE; OSMOTIC PUMP; PARKINSON DISEASE; PRODUCT DEVELOPMENT; SCANNING ELECTRON MICROSCOPY; TABLET FORMULATION; TABLET POROSITY; CHEMISTRY; EQUIPMENT DESIGN; EVALUATION; INSTRUMENTATION; OSMOLARITY; TABLET;

ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EQUIPMENT DESIGN; OSMOLAR CONCENTRATION; PARKINSON DISEASE; TABLETS;

EID: 42449106994     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Verma, R.K., Murali, D.M, Garg, S. "Formulation aspects in the development of osmotically controlled oral drug delivery systems". J.Controlled Release, 2002, 79, 7-27.
2. Santus, G.; Baker, W. "Osmotic drug delivery: a review of the patent literature". J.Controlled Release, 1995, 35, 1-21.
3. Gondaliya, D.; Pundarikashudu, K. "The fabrication and evaluation of the formulation variables of a controlled porosity osmotic drug delivery system with diltiazem hydrochloride", Pharm. Technology, 2003, 58,68.
4. Prabhakaran, D.; Singh, P.; Kanaujia, P.;.Jaganathan, K.S.; Vyas, S.P."Modified push-pull osmotic system for simultaneous delivery of theophylline and salbutamol:development and in-vitro characterization", Int.J.Pharm. 2004, 284, 95-108.
5. McClelland, G.A.; Sulton, S.C.; Engle, K.;. Zentner, G.M. "The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride" Pharm. Res., 1991, 8 (1), 88-92.
6. Zentner, G.M.; McClelland, G.A.; Sulton, S.C. "Controlled porosity solubility- and resin-modulated osmotic drug delivery clinical systems for release of diltiazem hydrochloride" J. Controlled. Release, 1991, 16, 237-244.
7. Zentner, G.M.; Rork, G.S.; Himmelstein, K.J. "Controlled Porosity Osmotic Pump", U.S. Patent, 4,968,507, 1990.
8. Zentner, G.M.; Rork, G.S.;.Himmelstein, K.J. "The controlled porosity osmotic pump", J. Controlled Release, 1985, 4, 269-282.
9. Appel, L.E.; Zentner, G.M. "Use of modified ethyl-cellulose lattices for microporous coating of osmotic tablets", Pharm.Res., 1991, 8 (5), 600-604.
10. McClelland, G.A.;Stubbs, R.J.; Fix, J.A.; Pogany, S.A.; Zentner, G.M. "Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form", Pharm. Res., 1991, 8, 873-876.
11. Appel, L.E.;. Clair, J.H.; Zentner, G.M. "Formulation and optimization of a modified microporous cellulose acetate latex coating for osmotic pumps", Pharm. Res., 1992, 12, 1664-1667.
12. Edgren, E.D.; Carpenter, H.A.;Bhatti, G.K. Ayer, A.D. "Antiparkinson Dosage Form". U.S. Patent 6,217,905, 2001.
13. Benbir, G.; Ozekmeksi, S.; Apaydin, H.; Delil S.; Erginoz E. "A Hospital based study: Risk factors in development of motor complications in 555 Pakinson's patients on levodopa therapy", Clinical Neuology and Neurosurgery, 2006, 108, 726-732.
14. Imamura, A.; Uitti, R.; Wszolek, Z. "Dopamine agonist therapy for Parkinson Disease and pathological gambling", Parkinsonism and Related Disorders, short communication, 2006, 12,506-508.
15. Lang, A.E., "Neuroprotection in parkinson's disease, and now for something completely different?" The Lancet Neurology, 2006, 5, 990-99.
16. Liu,X.; Chen,D.; Zhang,R. "Evaluation of monolithic osmotic tablet system for nifedipine delivery in-vitro and in-vivo", Drug Dev.Ind.Pharm., 2003, 29,813-819.
17. Liu,L.; Che,B. "Preparation of monolithic osmotic pump system by coating the indented core tablet", Eur. J. Pharm. Biopharm. 2006, 64,180-184.
18. Herbig, S.M.; Cardinal, J.R.; Korsmeyer, R.W.; Smith, K.L. "Asymmetric-membrane tablet coatings for osmotic drug delivery", J.Controlled Release, 1995, 35,127-136.
19. Verma,R.; Garg,S.; "Development and evaluation of osmotically controlled oral drug delivery system of glipizide", Eur. J.Pharm.Biopharm, 2004, 57,513-525.
20. Rani, M.; Mishra,B. "Comparative in Vitro and in Vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium", AAPS PharmSciTech., 2004, 5,4.
21. Thombre, A.G.;Zentner, G.M.; Himmelstein, K.J. "Mechanism of water transport in controlled porosity osmotic device", J.Membr.Sci., 1989, 40, 279-310.